For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Intravenous Oxytocin Infusion Study Day | Oxytocin 14 micrograms infusion over 30 minutes on first study day. | 0 | None | 0 | 24 | 4 | 24 | View |
| Intranasal Oxytocin Spray Study Day | Oxytocin 102 micrograms by intranasal spray on second study day. | 0 | None | 0 | 24 | 3 | 24 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Rhinorrhea after intranasal oxytocin | NON_SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (10.0) | View |
| Sternutation after intranasal oxytocin | NON_SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (10.0) | View |
| Feeling of warmth after intravenous oxytocin | NON_SYSTEMATIC_ASSESSMENT | General disorders | MedDRA (10.0) | View |
| Red face after intravenous oxytocin | NON_SYSTEMATIC_ASSESSMENT | Vascular disorders | MedDRA (10.0) | View |